학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 41건 | 목록 1~20
Academic Journal
Roller A; Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland andreas.roller@roche.com iakov.davydov@roche.com.; Davydov II; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland andreas.roller@roche.com iakov.davydov@roche.com.; Schwalie PC; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Serrano-Serrano ML; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Heller A; Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center, Roche Diagnostics GmbH, Munich, Germany.; Staedler N; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Ferreira CS; Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center, Roche Diagnostics GmbH, Munich, Germany.; Dietmann G; Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center, Roche Diagnostics GmbH, Munich, Germany.; Klaman I; Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center, Roche Diagnostics GmbH, Munich, Germany.; Valdeolivas A; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Korski K; Roche Product Development, PHC Data, Analytics and Imaging, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Cannarile MA; Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center, Roche Diagnostics GmbH, Munich, Germany.
Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Academic Journal
Cannarile MA; Roche Diagnostics GmbH, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Karanikas V; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland.; Reis B; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Mancao C; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Lagkadinou E; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Rüttinger D; Roche Diagnostics GmbH, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Rieder N; Roche Diagnostics GmbH, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Ribeiro FR; Roche Diagnostics GmbH, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Kao H; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Dziadek S; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Gomes B; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Machiels JP; Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium jean-pascal.machiels@uclouvain.be.; UCLouvain, Brussels, Belgium.; Gomez-Roca C; Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.; Michot JM; Department of Innovative Therapies and Early Phase trials (DITEP), Gustave Roussy, Villejuif, France.; Zamarin D; Memorial Sloan Kettering Cancer Center, New York City, New York, USA.; Mitchell T; Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Catala G; Medial Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.; Eberst L; Department of Medicine, Centre Léon Bérard, Lyon, France.; Jacob W; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Jegg AM; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Cannarile MA; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Watson C; A4P Ltd, Sandwich, UK.; Babitzki G; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Korski K; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Klaman I; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Teixeira P; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Hoves S; Roche Innovat Ctr Munich Oncol Discovery Pharma, Penzberg, Germany.; Ries C; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Meneses-Lorente G; Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Michielin F; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Christen R; Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Rüttinger D; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Weisser M; Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Delord JP; Department of Medicine, Centre Léon Bérard, Lyon, France.; Cassier P; Department of Medicine, Centre Léon Bérard, Lyon, France.
Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Academic Journal
Thakur MD; Genentech, South San Francisco, CA, USA. Electronic address: das-thakur.meghna@gene.com.; Franz CJ; Lake Tahoe Community College, South Lake Tahoe, CA, USA.; Brennan L; Roche Pharma Research and Early Development, Early Biomarker Development Oncology, Roche Innovation Center New York, Little Falls, NJ, USA.; Brouwer-Visser J; Roche Pharma Research and Early Development, Early Biomarker Development Oncology, Roche Innovation Center New York, Little Falls, NJ, USA.; Tam R; Genentech, South San Francisco, CA, USA.; Korski K; Roche Innovation Center Munich, Pharma Research and Early Development, Penzberg, Germany.; Koeppen H; Genentech, South San Francisco, CA, USA.; Ziai J; Genentech, South San Francisco, CA, USA.; Babitzki G; Roche Diagnostics GmbH, Penzberg, Germany.; Ranchere-Vince D; Département d'Anatomo-Pathologie, Centre Léon Bérard, Lyon, France.; Vasiljevic A; Team Fluid, INSERM U1028, CNRS UMR 5292, Lyon Neurosciences Recherche Center, Université Lyon 1, Lyon, France.; Dijoud F; Centre de Pathologie Est, Hospices Civils de Lyon, Université Lyon 1, Lyon, France.; Marec-Bérard P; Institut d'Hématologie et d'Oncologie Pédiatrique (iHOPe), Centre Léon Bérard, Lyon, France.; Rochet I; Institut d'Hématologie et d'Oncologie Pédiatrique (iHOPe), Centre Léon Bérard, Lyon, France.; Cannarile MA; Roche Innovation Center Munich, Pharma Research and Early Development, Penzberg, Germany.; Marabelle A; Institut d'Hématologie et d'Oncologie Pédiatrique (iHOPe), Centre Léon Bérard, Lyon, France; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Laboratoire de Recherche Translationelle en Immunothérapies, INSERM U1015, Gustave Roussy, Villejuif, France; Centre d'Investigation Clinique BIOTHERIS, INSERM CIC1428, Gustave Roussy, Villejuif, France; Faculté de Médecine, Université Paris Saclay, Le Kremlin-Bicetre, France. Electronic address: aurelien.marabelle@gustaveroussy.fr.
Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Academic Journal
Gomez-Roca C; Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, Toulouse, France gomez-roca.carlos@iuct-oncopole.fr.; Cassier P; Department of Medicine, Centre Leon Berard, Lyon, France.; Zamarin D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.; Machiels JP; Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.; Perez Gracia JL; Department of Oncology, Universidad de Navarra, Pamplona, UK.; Stephen Hodi F; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Taus A; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.; Martinez Garcia M; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.; Boni V; Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain.; Eder JP; Department of Medical Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA.; Hafez N; Department of Medical Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA.; Sullivan R; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.; Mcdermott D; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.; Champiat S; Drug Development Department, Gustave Roussy Institute, Villejuif, France.; Aspeslagh S; Drug Development Department, Gustave Roussy Institute, Villejuif, France.; Terret C; Department of Medicine, Centre Leon Berard, Lyon, France.; Jegg AM; Roche Innovation Center Munich, Penzberg, Germany.; Jacob W; Roche Innovation Center Munich, Penzberg, Germany.; Cannarile MA; Roche Innovation Center Munich, Penzberg, Germany.; Ries C; Roche Innovation Center Munich, Penzberg, Germany.; Korski K; Roche Innovation Center Munich, Penzberg, Germany.; Michielin F; Roche Innovation Center Basel, Basel, Switzerland.; Christen R; Roche Innovation Center Basel, Basel, Switzerland.; Babitzki G; Roche Innovation Center Munich, Penzberg, Germany.; Watson C; A4P Ltd, Sandwich, UK.; Meneses-Lorente G; Roche Innovation Center Welwyn, Welwyn Garden City, UK.; Weisser M; Roche Innovation Center Munich, Penzberg, Germany.; Rüttinger D; Roche Innovation Center Munich, Penzberg, Germany.; Delord JP; Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, Toulouse, France.; Marabelle A; Drug Development Department, Gustave Roussy Institute, Villejuif, France.
Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Academic Journal
Cannarile MA; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Gomes B; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Canamero M; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.; Reis B; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.; Byrd A; Genentech, South San Francisco, California.; Charo J; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland.; Yadav M; Genentech, South San Francisco, California.; Karanikas V; F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland. vaios.karanikas@roche.com.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Cannarile MA; Roche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, Germany.; Ries CH; Roche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, Germany.; Hoves S; Roche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, Germany.; Rüttinger D; Roche Pharmaceutical Research and Early Development; Discovery Oncology ; Roche Innovation Center Penzberg ; Penzberg, Germany.
Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Academic Journal
Gomez-Roca CA; Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse. Electronic address: gomez-roca.carlos@iuct-oncopole.fr.; Italiano A; Department of Medical Oncology, Institut Bergonié, Bordeaux. Electronic address: a.italiano@bordeaux.unicancer.fr.; Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud; INSERM U900 Research Unit, Saint-Cloud; Paris-Saclay University, Paris.; Cassier PA; Department of Medicine, Centre Léon Bérard, Lyon, France.; Toulmonde M; Department of Medical Oncology, Institut Bergonié, Bordeaux.; D'Angelo SP; Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York, USA.; Campone M; ICO René Gauducheau, Saint-Herblain, France.; Weber KL; Department of Orthopedic Oncology, Penn Medicine, Pennsylvania, USA.; Loirat D; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud.; Cannarile MA; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Jegg AM; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Ries C; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Christen R; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.; Meneses-Lorente G; Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn Garden City.; Jacob W; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Klaman I; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Ooi CH; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.; Watson C; A4P Consulting Ltd, Sandwich, UK.; Wonde K; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.; Reis B; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.; Michielin F; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.; Rüttinger D; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Delord JP; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud.; Blay JY; Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse.
Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Academic Journal
Cannarile MA; Division of Biological Sciences, University of California, San Diego, La Jolla, California 92093, USA.; Lind NARivera RSheridan ADCamfield KAWu BBCheung KPDing ZGoldrath AW
Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1529-2908 (Print) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE
Academic Journal
Pao W; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland. william.pao@roche.com.; Ooi CH; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Birzele F; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Ruefli-Brasse A; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Cannarile MA; Roche Innovation Center Munich, F. Hoffmann-La Roche AG, Munich, Germany.; Reis B; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Scharf SH; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Schubert DA; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Hatje K; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Pelletier N; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Spleiss O; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.; Reed JC; Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Academic Journal
Hoves S; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany sabine.hoves@roche.com.; Ooi CH; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Wolter C; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Sade H; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Bissinger S; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Schmittnaegel M; Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.; Ast O; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Giusti AM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Wartha K; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Runza V; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Xu W; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Kienast Y; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Cannarile MA; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Levitsky H; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland.; Romagnoli S; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; De Palma M; Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.; Rüttinger D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Ries CH; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany carola.ries@roche.com.
Publisher: Rockefeller University Press Country of Publication: United States NLM ID: 2985109R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-9538 (Electronic) Linking ISSN: 00221007 NLM ISO Abbreviation: J Exp Med Subsets: MEDLINE
Academic Journal
Cannarile MA; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377, Germany. Michael.cannarile@roche.com.; Weisser M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377, Germany.; Jacob W; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377, Germany.; Jegg AM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377, Germany.; Ries CH; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377, Germany.; Rüttinger D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377, Germany.
Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Academic Journal
Pradel LP; Roche Innovation Center Munich, Discovery Oncology Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Paris Lodron University Salzburg, Natural Sciences Faculty, Salzburg, Austria.; Ooi CH; Roche Innovation Center Basel, Pharmaceutical Research and Early Development, Basel, Switzerland.; Romagnoli S; Roche Diagnostics, Global Business Development Division, Biomarker Programs, Basel, Switzerland.; Cannarile MA; Roche Innovation Center Munich, Discovery Oncology Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Sade H; Roche Innovation Center Munich, Discovery Oncology Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Rüttinger D; Roche Innovation Center Munich, Discovery Oncology Roche Pharmaceutical Research and Early Development, Penzberg, Germany.; Ries CH; Roche Innovation Center Munich, Discovery Oncology Roche Pharmaceutical Research and Early Development, Penzberg, Germany. carola.ries@roche.com.
Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Cannarile, MA
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어